BioSpace News Archive

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company has signed a group purchasing agreement with HealthTrust Purchasing Group, L.P. (HealthTrust) for its full portfolio of OviTex® hernia repair and OviTex® PRS products.

Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored with a 2019 MarCom Platinum Award.

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, reported that China’s National Health Commission recently issued a new policy allowing the relevant Provincial Health Commissions to approve cord blood bank licenses in 18 pilot Free Trade Zones in China.

Apexigen, Inc. announced today the appointments of Jason Wright, Ph.D., as Vice President, CMC and Thomas Jahn, M.D., Ph.D., as Vice President, Clinical Development

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of fimepinostat, a small molecule dual inhibitor of PI3K/HDAC and suppressor of MYC, in combination with venetoclax,

UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE study.

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling study of RP-L102 “Process B” received investigational therapy.

Investor and analyst event to be held on Monday, December 9, 2019 at 7:30 PM ET at the Hyatt Regency Orlando featuring a fireside chat with leading clinical investigators

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), and Inceptua Medicines Access (a business unit of the Inceptua Group), today announced that they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.